Landscape of genomic alterations across 51 patients with ductal prostate cancer. Each column represents one patient. Pathogenic mutations were those predicted to either activate oncogenic signaling pathways (eg, WNT- or PI3K-signaling) or inactivate tumor suppressors (eg, DNA damage repair [DDR] genes, TP53). HR, homologous recombination; MMR, mismatch repair; VUS, variant of uncertain significance.